Does aging weaken T-cell immune surveillance of latent Epstein-Barr virus?

EBV persists lifelong in latency and can enter lytic replication. In a 74-year-old, age-related changes in cellular immunity make less efficient EBV control biologically credible, but not inevitable or uniform.

Clinical and virologic evidence

• Aging is plausibly associated with less effective EBV control. In one older-versus-younger study, older adults had far higher EBV DNA in B cells (175,101 versus 15 genomes per million B cells), detectable plasma EBV DNA in 37%, late/lytic viral transcripts, and lytic-antigen-reactive CD8+ cells—findings interpreted as ongoing reactivation rather than latency alone.
• A separate study found plasma EBV DNA more frequently in older women, although viral loads did not differ significantly. Conversely, a larger blood-virome study found no age association with EBV RNA, and a life-course cohort found no association between detectable EBV-specific T-cell responses and EBV DNA in saliva or blood.

T-cell and mechanistic evidence

• Advanced age can affect EBV-specific T-cell quality more clearly than cell number. Among adults older than 87, EBV-tetramer-positive CD8+ cells were more frequent, but a smaller proportion produced IFN-γ after stimulation, consistent with accumulation of less immediately functional antiviral clones.
• Older age is associated with reduced diversity of the EBV-specific T-cell receptor repertoire. A narrower repertoire could limit recognition of infected cells expressing different EBV antigens. CMV infection was associated with an additional reduction in EBV-specific repertoire diversity.
• However, EBV-specific responses can be preserved or even increased in some older groups, depending on CMV status, antigen tested, and assay; increased cell counts or cytokine responses do not necessarily establish better viral containment.

Bottom line

• The claim is plausible with moderate confidence: aging may weaken aspects of EBV-directed T-cell surveillance and is associated in some cohorts with markers compatible with poorer control or reactivation. The evidence supports heterogeneous, context-dependent risk—not a proven, universal causal pathway from age to EBV reactivation.